Ionis is hoping to gain approval of Trygolza in severe hypertriglyceridemia which could set to to generate $2bn in sales.

Earlier this week, GSK and Ionis Pharmaceuticals reported that their antisense drug bepirovirsen achieved primary endpoints ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

35-week data included in the filing demonstrated a statistically significant and clinically meaningful change from baseline for co-primary and secondary endpoints compared to external placebo group ...

GSK and Ionis report strong Phase 3 results for a hepatitis B drug that improved cure rates and could support regulatory filings in early 2026.

Ionis Pharmaceuticals remains a Buy after Dawnzera's FDA approval, which strengthens its pipeline and revenue outlook despite a history of operating losses. Dawnzera's market opportunity in hereditary ...

HC Wainwright initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a commercial-stage biotech company focused on RNA-targeted therapeutics. Analyst Mitchell Kapoor says Ionis has used its ...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTT Rx for the treatment of patients with ...